Medical Writing Good Pharma Sunshine spreading across the Atlantic and over Europe
mew-150pxjpg

Volume 22, Issue 4 - Good Pharma

Sunshine spreading across the Atlantic and over Europe

Abstract

The quest for transparency in the relationships between life sciences companies and healthcare professionals is quickly becoming a global movement. Reporting requirements for financial interactions have been prevalent in the United States for many years, but the movement is spreading throughout the world to places like Japan, Australia, and Europe. In France, the government passed a law that imposes burdensome reporting requirements. Industry groups across Europe, most notably the European Federation of Pharmaceutical Industries and Associations, are acting aggressively to try to forestall more government laws by adopting industry-developed disclosure systems. These activities will affect many different segments of the European healthcare system.

Download the full article

References

  1. EFPIA Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations, efpia.eu Available from: http://transparency.efpia.eu/the-efpia-code-2
  2. LOI n 2011-2012 du 29 décembre 2011 relative au renforcement de la sécurité sanitaire du médicament et des produits de santé.
  3. Décret n° 2013-413 du 21 mai 2013 portant approbation de la charte de l'expertise sanitaire prévue à l'article L. 1452-2 du code de la santé publique.
  4. Circular No. DGS/PF2/2013/224 of May 29, 2013 regarding the application of Article 2 of LOI n 2011-2012 of December 29, 2011 increasing the safety for health purposes of drugs and healthcare products.
  5. EFPIA Code on the Promotion of Prescription-Only Medicines to, and Interactions with Healthcare Professionals, efpia.eu. Available from: http://transparency.efpia.eu/documents/9/20/EFPIA-HCP-Code-2013
  6. EFPIA Code of Practice on Relationships Between the Pharmaceutical Industry and Patient Organisations, efpia.eu Available from: http://www.efpia.eu/documents/23/111/EFPIA-Code-of-Practice-on-relationships-between-the-pharmaceutical-industry-and-patient-organisations-Amended-by-decision-of-the-General-Assembly-in-June-2011

Search

Articles

Good pharma
Message from the President
Transparency and the healthcare industry: The Sun is shining
Sunshine spreading across the Atlantic and over Europe
Bad karma
If a misinformed voice speaks out in the wilderness and no one refutes it, does it make a sound? A call to advocacy
The Big Pharma conspiracy theory
Editorial: Pharmaism
Legal remedies for medical ghostwriting: Imposing fraud liability on guest authors of ghostwritten articles
A decade of change: A new ISMPP has arrived
Selling evidence over the counter: Do community pharmacists engage with evidence-based medicine?
Good regulatory practice and the role(s) of a regulatory affairs professional
Profile: An interview with Dr Gustavo A. Silva on the concept of public health in medical writing and translation
AuthorAID: An international service and chance to serve
India as a hub for ethical and evidence-based medical communications
Providing value for medicines in older people
In the Bookstores
Journal Watch
The Webscout
Regulatory Writing
Medical Communications
Manuscript Writing
Out On Our Own
Erratum
The Light Stuff

Member Login

Links

The Write Stuff Archive Contact Instructions for Authors Feature Article Template (Word) Journal Policies

Editoral Board

Editor-in-Chief:

Co-Editor:

Editorial Manager

  • Victoria White (Tampa, Florida, USA)
show all +

Associate Editors:

Section Editors:

Ad-hoc Editors:

  • Amy Whereat (SpeaktheSpeech Consulting, Asnieres sur Seine, France)

Editor Emeritus: